[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperglycemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperglycemia":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,38,0,25,[9,48,81,108,131,162,190,213,247,269,295,327,366,392,422,443,469,508,534,556,579,602,630,661,693],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100525222","time-restricted-eating-window-timing-type-2-diabetes-status-and-sex-on-glycemic-control-100525222",false,"NCT06118931","Time-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic Control","The Impact of Time-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic Control","Inclusion Criteria:\n\n* Aged 40 years or older\n* Body mass index \\\u003C50 kg\u002Fm2\n* Have access to an Apple or Android cellphone with Bluetooth.\n* Have type 2 diabetes or be at risk for type 2 diabetes (defined as self-report of pre-diabetes, a recent (within 12 months) measure of HbA1c between 5.7 and 6.4%, waist circumference (WC) that is BMI specific; for women: BMI \\>= 18.5-24.9, WC \\>= 80cm; BMI \\>= 25-29.9, WC \\>= 90cm; BMI \\>= 30-34.9, WC \\>= 105cm; BMI \\>= 35+, WC \\>= 115cm; for men: BMI \\>= 18.5-24.9, WC \\>= 90cm; BMI \\>= 25-29.9, WC \\>= 100cm; BMI \\>= 30-34.9, WC \\>= 110cm; BMI \\>= 35+, WC \\>= 125cm.\n\nExclusion Criteria:\n\n* Individuals with type 2 diabetes will be excluded if: (1) currently on \\>2 monotherapies for diabetes, (2) have had diabetes therapy medication or dosage changes \\\u003C3 months, (3) self-reported hemoglobin A1c \\>9.0%, (4) taking exogenous insulin, or (5) taking sulfonylureas\n* The following exclusion criteria applies to all potential participants:\n\n  1. History of or referral for bariatric surgery\n  2. Weight loss \\>3% in the last 3 months\n  3. Taking antiobesity (weight loss) medications\n  4. Body weight \\>390lbs\n  5. Diagnosed with severe cognitive disorder that precludes them from giving consent\n  6. Inability or unwillingness to change their eating window to follow those prescribed in the study\n  7. Currently consistently eating during \\\u003C11.5 hour period .\n  8. Physician-diagnosed eating disorder\n  9. Having a pacemaker or receiving dialysis.\n  10. Not having access to a Lifelabs location.","ALL","40 Years",{"count":20,"type":21},123,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study will evaluate the effectiveness of time-restricted eating (TRE), which is a form of intermittent fasting. When performing TRE, individuals consume all of their calories within a specific time window and then only consume water or other no calorie drinks the rest of the day. TRE is performed each day. There is no restriction on the quality or amount of food that people can consume during their eating window (ad libitum eating) with TRE, which can last anywhere from 4 to 12 hours. We are comparing three different 9-hour eating windows to determine whether the start and stop time of the eating window impact blood sugar control in individuals with obesity who also have or are at risk for type 2 diabetes. We also aim to determine if there are differences in the effects of the timing of eating window between males and females.",[27,28,29,30],"Diabetes Mellitus, Type 2","Obesity","Prediabetic State","Hyperglycemia",[32,33,28,34],"Time-restricted eating","Type 2 Diabetes","Glycemic Control","RECRUITING","2026-06-26",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":39},"2025-06-28",{"date":43,"type":21},"2027-06-28",{"name":45,"class":46},"University of Toronto","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":47},"100641794","personality-traits-and-biochemical-risk-phenotypes-100641794","NCT07653048","Personality Traits and Biochemical Risk Phenotypes","Personality Traits and Biochemical Risk Phenotypes in Adults Undergoing Routine Health Assessment","PHEBiP","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Undergoing routine health assessment\n* Completion of the Five-Factor Personality Inventory (FFPI)\n* Availability of routine laboratory test results\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Incomplete FFPI assessment\n* Missing or incomplete laboratory data\n* Refusal or inability to provide informed consent",true,"18 Years",{"count":59,"type":21},1000,"OBSERVATIONAL","This prospective observational study investigates the association between personality traits and routine laboratory abnormalities in adults undergoing routine health assessment. Personality traits are assessed using the Five-Factor Personality Inventory (FFPI), while biochemical data are obtained from routine laboratory testing, including markers of glycemic status, liver function, lipid metabolism, renal function, and complete blood count parameters.\n\nThe primary objective of the study is to evaluate the association between FFPI personality trait scores and the total number of laboratory abnormalities identified during routine clinical evaluation. Secondary analyses will examine associations between personality traits and glycemic status, fasting plasma glucose concentration, liver function markers, lipid profile parameters, renal function indicators, complete blood count parameters, and the total number of laboratory abnormalities.\n\nThe findings may contribute to a better understanding of the relationship between psychological characteristics and biological health indicators and may support the development of more personalized approaches to health promotion, risk assessment, and disease prevention.",[63,30,64],"Prediabetes","Metabolic Syndrome",[66,67,63,30,68,69,70,71],"Personality Traits","Biomarkers","Occupational Health","Five-Factor Personality Inventory","Laboratory Abnormalities","Routine Health Assessment","2026-06-11",{"date":74,"type":39},"2026-06-17",{"date":76,"type":39},"2024-10-01",{"date":78,"type":21},"2027-09-01",{"name":80,"class":46},"Medical Center TOPMED",{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":104,"leadSponsor":106,"locationsCount":47},"100640569","regional-innovation-in-chronic-disease-and-elderly-care-100640569","NCT07578090","Regional Innovation in Chronic Disease and Elderly Care","A Regional Integrated Care Innovation Program for Cardiometabolic Health, Pulmonary-Circulatory Disease Management, and Elderly Support","Inclusion Criteria:\n\n* Participants with hypertension, hyperglycemia, or hyperlipidemia who meet at least one of these criteria are eligible for enrollment.\n\nExclusion Criteria:\n\n* Age under 18 years\n* Patients diagnosed with neuromuscular disorders\n* Inability to perform cardiopulmonary exercise testing\n* Refusal to participate in the study",{"count":59,"type":21},"This project aims to develop a community-based health promotion intervention model for populations at potential risk of metabolic syndrome. Through exercise training and lifestyle modifications, the project seeks to improve cardiopulmonary function and disease control, align with current public health policies, and establish an evidence-based model with strong potential for broader implementation.",[91,92,93,30],"Hypertension","Cardiovascular Disease","Hyperlipidemia",[95,96,97,98,99],"hypertension","exercise training","cardiovascular disease","hyperlipidemia","hyperglycemia","2026-05-26",{"date":102,"type":39},"2026-05-28",{"date":100,"type":39},{"date":105,"type":21},"2026-12-31",{"name":107,"class":46},"Fu Jen Catholic University",{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":47},"100432417","feasibility-of-using-the-cgm-guardian-2-interstitial-fluid-glucose-measurement-system-in-intensive-care-medicine-100432417","NCT04910841","Feasibility of Using the \"CGM GUARDIAN 2\" Interstitial Fluid Glucose Measurement System in Intensive Care Medicine","GALI","Inclusion Criteria:\n\n* Patient in septic shock\n* Arterial hypotension requiring noradrenaline\n* Hyperglycaemia requiring insulin therapy\n\nExclusion Criteria:\n\n* Patients under guardianship, curatorship or deprived of liberty\n* Pregnant or breastfeeding women",{"count":116,"type":21},55,[24],"Glycemic imbalances are very common in shock patients admitted to intensive care units. A blood glucose control every 2 hours is routinely performed in patients requiring insulin therapy. In practice, we use a protocol and management software called \"CPG\" (Personalized Control of Blood Glucose). This involves taking capillary samples from the fingertips. In addition to the pain generated, local haematomas and sensitivity disorders have been described. Night-time sampling also leads to repeated awakenings. The \"CGM GUARDIAN 2\" system has been validated for the measurement of glucose in interstitial fluid in insulin-dependent diabetic patients. An electrode is placed on the patient's abdomen or arm for up to 6 days. This electrode consists of a needle that is inserted subcutaneously only during the placement. The sugar level is read using a sensor placed on the electrode and an insulin pump (which will not deliver therapy (for our study) and which will be used only as an information reader to know the glucose level and trends). Interstitial fluid is automatically drawn from the electrode every minute and averaged every 5 minutes.\n\nThis device has not yet been validated in resuscitation patients.",[30,120,121],"Hypotension","Shock, Septic","2026-05-21",{"date":124,"type":39},"2026-05-22",{"date":126,"type":39},"2023-09-11",{"date":128,"type":21},"2026-09",{"name":130,"class":46},"Centre Hospitalier Universitaire de Nice",{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":147,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":161},"100473662","diabetes-clinical-decision-support-100473662","NCT05447806","Diabetes Clinical Decision Support","Glucose Management Clinical Decision Support to Improve Outcomes in Academic and Community Hospitals","Inclusion Criteria:\n\n* Hospitalized adult (\\>18 years) patients at Penn State Health, Hershey Medical Center, St. Joseph's Hospital, Hampden Medical Center, Holy Spirit Medical Center, and Lancaster Medical Center\n* Ambulatory adult (\\>18 years) patients at Penn State Health, Hershey Medical Center, St. Joseph's Hospital, Hampden Medical Center, Holy Spirit Medical Center, and Lancaster Medical Center\n* Trigger of an alert or a disease management message\n\nExclusion Criteria:\n\n* Children (\\\u003C18 years)",{"count":139,"type":21},15732,[24],"The purpose of this study is to determine the impact of an electronic medical record clinical decision support tool on rates of dysglycemia in the hospital, and its clinical and economical outcomes. The study also evaluates the perspectives of providers regarding the tool's usefulness on disease management support, knowledge, and practice performance.",[30,143,144,145,146],"Hyperglycemia Stress","Diabetes","PreDiabetes","Hypoglycemia",[148,149,150,151],"Clinical Decision Support","Electronic Medical Records","Health Systems Science","Hospital Management","2026-05-12",{"date":154,"type":39},"2026-05-14",{"date":156,"type":39},"2022-07-15",{"date":158,"type":21},"2026-10-16",{"name":160,"class":46},"Milton S. Hershey Medical Center",2,{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":12,"sex":17,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":174,"conditions":175,"keywords":176,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":47},"100584744","monitoring-exhaled-breath-to-noninvasively-detect-glycemic-events-100584744","NCT06893341","Monitoring Exhaled Breath to Noninvasively Detect Glycemic Events","Monitoring Volatile Organic Compound Profiles in Exhaled Breath to Noninvasively Detect Glycemic Events in Patients With Diabetes","Inclusion Criteria:\n\n* Who are diagnosed with type 1 diabetes.\n* Who are between 12-19 years of age.\n* That utilize a Dexcom (G6 or G7) continuous glucose monitoring device.\n* That have an established working CGM for at least 12 hours (that does not need to be replaced within 24 hours).\n* That are willing to share their daily CGM data for the study.\n* That are the only individuals in their household with any type of diabetes diagnosis (type 1 or type 2).\n* That are willing to return the device within 24-48 hours of study completion.\n* That are located in Indianapolis, IN or its suburban areas.\n\nExclusion Criteria:\n\n* That are smokers or use tobacco products or who live with someone who smokes in their vicinity.\n* That have a condition or abnormality other than type 1 diabetes that in the opinion of the Investigator would compromise the safety of the subject or the quality of the data.\n* That utilize closed-loop diabetes management systems.\n* That have symptoms or recently been diagnosed with an upper respiratory illness including COVID-19.\n* That themselves or a close family member (living within the same household at the time of the data collection period) is on a \"ketogenic diet\".\n* That themselves or a close family member is working in an industry with high and continuous exposure to exogenous VOCs. Examples of such industries include beauty salons and paint manufacturers.\n* That are unable or unwilling to cooperate with sample collection.","12 Years","19 Years",{"count":172,"type":21},30,[24],"The purpose of this study is to determine whether an array of biosensors can noninvasively identify hyperglycemic or hypoglycemic events in persons diagnosed with diabetes through noninvasive detection of volatile organic compounds in exhaled breath.",[144,30,146],[177,178,179,180],"Volatile Organic Compound (VOC)","Electronic Nose (e-Nose)","Exhaled Breath","Noninvasive Health Monitoring","2026-05-08",{"date":183,"type":39},"2026-05-13",{"date":185,"type":39},"2025-10-23",{"date":187,"type":21},"2026-12-01",{"name":189,"class":46},"Indiana University",{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":47},"100510955","a-study-of-glycemic-control-in-left-ventricular-assist-100510955","NCT05933161","A Study of Glycemic Control in Left Ventricular Assist","GLYcemic Control Evaluation by Continuous Glucose Monitor Compared With a1C in Left Ventricular Assist Device-supported Patients (GLYCEM1C-LVAD)","GLYCEM1C-LVAD","Inclusion Criteria:\n\n* Prior implantation of contemporary, centrifugal flow LVAD (HeartWare or HeartMate 3) at any time after 2010\n* Diagnosis of type II diabetes mellitus\n* Any antihyperglycemic regimen\n* Greater than 3 months out from LVAD implantation\n* Capable of utilizing smartphone device for LibreLink app for uploading glycemic data\n* Patients may be enrolled who have preexisting CGM in place.\n\nExclusion Criteria:\n\n* Type I diabetics\n* Unable to return at 3 month evaluation\n* Unwillingness to participate",{"count":199,"type":21},20,"The study is being conducted to understand if the hemoglobin A1c, a measurement of control of blood sugars over a 3-month time, is valid in patients with Left Ventricular Assist Devices (LVADs) in place. To understand whether it is an adequate measurement, the investigators will compare the A1c to results from a continuous glucose monitor (CGM) measurement of blood sugars. By monitoring blood sugars continuously, the investigators will also assess whether they can get better control of blood sugars with a CGM, including avoiding low blood sugars.",[202,30,146],"Type 2 Diabetes Mellitus",[204],"Left Ventricular Assist Device (LVAD)","2026-05-05",{"date":181,"type":39},{"date":208,"type":39},"2023-11-10",{"date":210,"type":21},"2027-07",{"name":212,"class":46},"Mayo Clinic",{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":17,"minAge":221,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":225,"briefSummary":226,"conditions":227,"keywords":230,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":47},"100638369","effects-of-short-and-long-courses-of-intermittent-hypoxic-hyperoxic-training-in-patients-with-type-2-diabetes-including-elderly-100638369","NCT07574333","Effects of Short and Long Courses of Intermittent Hypoxic-Hyperoxic Training in Patients With Type 2 Diabetes Including Elderly","A Single-Center Randomized Clinical Trial With Prospective Follow-up of the Efficacy and Safety of Short and Long Duration Intermittent Hypoxic-Hyperoxic Training in Patients With Type 2 Diabetes Mellitus Including Elderly Patients","EFIR","Inclusion Criteria:\n\n* Age 50-74 years inclusive\n* Type 2 diabetes mellitus confirmed by medical documentation\n* Stable therapy for diabetes and other chronic diseases for at least 4 weeks prior to enrollment\n* Ability to comply with study protocol requirements\n* Signed informed consent\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* Acute diabetes complications within 6 months (diabetic ketoacidosis, hyperosmolar hyperglycemic state, lactic acidosis, hypoglycemic coma)\n* Acute or active chronic infections\n* Angina pectoris functional class III-IV\n* Uncontrolled grade 3 arterial hypertension (SBP ≥180 and\u002For DBP ≥110 mmHg)\n* Acute cerebrovascular accident, myocardial infarction, surgical interventions, clinically significant injuries within 6 months\n* Internal carotid artery stenosis \\>60% and\u002For symptomatic stenosis 50-99%\n* Chronic obstructive pulmonary disease and bronchial asthma\n* Exacerbation and decompensation of chronic diseases within 1 month ALT and\u002For AST levels \\>2-3 times upper limit of normal\n* Congenital heart and major vessel abnormalities\n* Implanted cardiac pacemaker\n* Cancer with remission \\\u003C5 years\n* Mental illness, drug addiction, alcohol dependence\n* Pregnancy\n* Inability to participate throughout the study period","50 Years","74 Years",{"count":224,"type":21},250,[24],"This is a single-center randomized controlled trial evaluating the efficacy and safety of short (3 days) versus long (10 days) courses of intermittent hypoxic-hyperoxic training (IHHT) in patients with type 2 diabetes mellitus aged 50-74 years. Participants will be randomized into three groups: 3-day IHHT course (n≥100), 10-day IHHT course (n≥100), or control group receiving gas mixture with constant O2 21% for 10 days (n≥50). The primary outcomes are fasting glucose levels and HbA1c. Secondary outcomes include cardiovascular parameters, quality of life, cognitive function, and biological age.",[228,30,64,229],"Type 2 Diabetes Mellitus (T2DM)","Older Adults (65 Years and Older)",[231,232,202,233,234,235,236],"Intermittent hypoxic-hyperoxic training","T2DM","Glycemic control","Elderly patients","Non-pharmacological intervention","Hypoxia conditioning","2026-05-04",{"date":239,"type":39},"2026-05-07",{"date":241,"type":39},"2025-10-15",{"date":243,"type":21},"2027-12-15",{"name":245,"class":246},"National Medical Research Center for Therapy and Preventive Medicine","OTHER_GOV",{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":47},"100503421","phase-4-effect-of-zinc-on-glucose-homeostasis-100503421","NCT05835037","Effect of Zinc on Glucose Homeostasis","Clinical and Nutrigenetic Assessment of Zinc in Participants With Prediabetes","Inclusion Criteria:\n\n* Amish men or women who are 18 to 80 years old\n* Prediabetes (HgbA1c = 5.7-6.4% or fasting glucose levels 100-125 mg\u002FdL)\n\nExclusion Criteria:\n\n* Pregnant\n* Currently breastfeeding\n* History of severe gastrointestinal disorders or upper gastrointestinal surgery\n* Has hemochromatosis, cancer, liver disease, kidney disease, cardiovascular disease, or other coexisting malignancy\n* Hemoglobin \\\u003C 12.5 g\u002Fdl (male) or \\\u003C 11 g\u002Fdl (female)\n* Severe hypertension (blood pressure \\> 160\u002F95 mm Hg)\n* Has a creatinine greater than 2.0 mg\u002Fdl, aspartate aminotransferase (AST) or alanine transaminase (ALT) greater than 2 times the upper limit of normal, hematocrit (Hct) less than 32%, or thyroid-stimulating hormone (TSH) less than 0.4 or greater than 5.5 milli-international units (mIU) per liter.\n* At the discretion of the study physician or PI, taking medications that affect the outcomes of the study including, but not limited to, corticosteroids, anti-psychotic agents, protease inhibitors, oral contraceptives, estrogens, niacin, and some classes of antidepressants, statins, and antihypertensive medications\n* Zinc hypersensitivity\n* Use of denture adhesive containing zinc\n* Taking other medications or zinc-containing supplements and is unwilling or cannot safely, in the opinion of the study physician, discontinue their use at least 2 weeks prior to protocol initiation\n* Any other condition that would, in the opinion of the investigator, place them at an unacceptable risk or render them unable to meet the requirements of the protocol.","80 Years",{"count":256,"type":21},200,[258],"PHASE4","The purpose of this investigation is to evaluate the impact of zinc supplementation on fasting glucose levels, hemoglobin A1c (HbA1c), and other indices of glucose homeostasis in individuals with prediabetes. The investigators hypothesize that prediabetic subjects receiving zinc will demonstrate a greater decrease in HbA1c and blood glucose compared to prediabetic subjects receiving placebo.\n\nSpecific Aim: Conduct a prospective, double-blind randomized clinical trial comparing the effects of 12 months of zinc supplementation (zinc gluconate 30 milligram \\[mg\\] per day) versus placebo on glucose homeostasis. Based upon expected effect size and power calculations, and anticipating a 20% drop-out rate, the investigators will study 200 prediabetic subjects (100 per group) using a 1:1 randomization design. HbA1c, fasting plasma glucose, and other measures will be obtained at 0, 6, and 12 months and will be compared between zinc supplementation and placebo groups.",[29,30],"2026-04-28",{"date":205,"type":39},{"date":264,"type":39},"2024-02-16",{"date":266,"type":21},"2028-07",{"name":268,"class":46},"University of Maryland, Baltimore",{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":17,"minAge":276,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":285,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":47},"100544943","real-time-engagement-for-learning-to-effectively-control-type-2-diabetes-100544943","NCT06375460","Real-time Engagement for Learning to Effectively Control Type 2 Diabetes","REFLECT2D","Inclusion Criteria:\n\n* type 2 diabetes: negative diabetes autoantibodies, no suspicion for monogenic diabetes\n* HbA1c ≥7.0%, stable medication use\n* HbA1c 6.0-6.9% without short-acting insulin, any other stable diabetes medication use\n* English-speaking (app in English)\n\nExclusion Criteria:\n\n* Current pregnancy\n* Hydroxyurea use (CGM sensor inaccuracies)\n* Cognitive impairment or severe psychiatric condition that could interfere with participation in behavioral intervention for diabetes self-management\n* Current or previously diagnosed eating disorder","16 Years","24 Years",{"count":279,"type":21},100,[24],"This is a clinical trial that includes a run-in period, a 90 day micro-randomized trial, and a 90-day observational period. The goal of this study is to evaluate whether providing paired real time glycemic and health behavior data in a smartphone app leads to better glycemic control among adolescents and young adults with T2D. Glycemic control will be monitored using Continuous Glucose Monitors (CGM), and health behavior data will be collected via a Fitbit activity tracker and a research app (Healthmine). Participants will be prompted to view and reflect on glycemic trends and health behavior data (Fitbit data, logging of diet and medication adherence) during the 90-day micro-randomized trial period, then observed for ongoing use of the Healthmine app and engagement with CGM in the following 90-day observation period.",[27,283,30,284],"Lifestyle","Physical Inactivity","NOT_YET_RECRUITING","2026-04-22",{"date":288,"type":39},"2026-04-24",{"date":290,"type":21},"2026-07",{"date":292,"type":21},"2029-08",{"name":294,"class":46},"University of Pittsburgh",{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":17,"minAge":303,"maxAge":304,"enrollmentInfo":305,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":307,"conditions":308,"keywords":313,"overallStatus":285,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":325,"locationsCount":47},"100614529","cgm-based-glycemic-analysis-after-esi-100614529","NCT07280780","CGM-Based Glycemic Analysis After ESI","Continuous Glucose Monitoring-Based Evaluation of Glycemic Fluctuations Following Epidural Steroid Injections: A Comparative Study by Diabetic Status","CGMSteroid","Inclusion Criteria:\n\n* Adults aged 20 to 60 years.\n* Patients scheduled for cervical or lumbar epidural steroid injection at the pain clinic.\n* Patients capable of understanding and using a Continuous Glucose Monitoring (CGM) device.\n\nExclusion Criteria:\n\n* Patients currently taking or administering steroid medications.\n* Patients with Type 1 Diabetes Mellitus.\n* Patients with Cushing's disease.\n* Patients who have received an epidural steroid injection within the last 3 months.\n* Patients with a known allergy to contrast media.\n* Patients taking anticoagulants or antiplatelet agents.\n* Patients unable to use a Continuous Glucose Monitoring (CGM) device.","20 Years","60 Years",{"count":306,"type":21},36,"The goal of this clinical study is to learn how blood glucose levels change after an epidural steroid injection (ESI) with dexamethasone in adults. It will specifically compare the glycemic response between patients with type 2 diabetes and those without diabetes.\n\nThe main questions it aims to answer are:\n\nDoes the injection cause higher or longer-lasting blood glucose elevation in diabetic patients compared to non-diabetic patients? How do the mean glucose level and Time in Range (TIR) change after the injection in both groups?\n\nResearchers will compare a Type 2 Diabetes group to a Non-Diabetes group to see the differences in glycemic fluctuations using a continuous glucose monitoring (CGM) device.\n\nParticipants will:\n\n* Wear a small CGM sensor on their arm for about 15 days to monitor blood glucose levels continuously\n* Receive an epidural steroid injection containing 5 mg of dexamethasone on Day 3\n* Visit the clinic 3 times (Day 1, Day 3, and Day 15) for sensor attachment, the injection procedure, and data collection",[309,30,310,311,312],"Type 2 Diabetes (T2DM)","Radicular Pain","Spinal Stenosis","Intervertebral Disc Herniation",[314,315,316,317,318],"epidural steroid injection","Continuous Glucose Monitoring","Dexamethasone","Glycemic Variability","Time in range","2026-04-07",{"date":321,"type":39},"2026-04-09",{"date":323,"type":21},"2026-04-20",{"date":105,"type":21},{"name":326,"class":46},"Korea University Anam Hospital",{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":337,"conditions":338,"keywords":342,"overallStatus":285,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":365},"100631644","standardized-italian-network-enrolling-individuals-with-islet-autoantibodies-100631644","NCT07503366","Standardized Italian netwoRk Enrolling iNdividuals With Islet-Autoantibodies","Standardized Italian netwoRk Enrolling iNdividuals With Islet-Autoantibodies (SIRENA)","SIRENA","Inclusion Criteria:\n\n* Individuals of any age who test positive for at least one islet autoantibody.\n* Absence of clinical symptoms of diabetes.\n* Do not meet ADA diagnostic criteria for diabetes (no overt hyperglycemia).\n* Ability to comply with follow-up procedures according to clinical practice.\n* Written informed consent obtained from the participant or, for minors, from a parent or legal guardian.\n\nExclusion Criteria:\n\n* Prior diagnosis of type 1 or type 2 diabetes.\n* Fasting plasma glucose ≥126 mg\u002FdL, HbA1c ≥6.5%, or OGTT 2-hour glucose ≥200 mg\u002FdL.\n* Presence of symptoms suggestive of diabetes (e.g., polyuria, polydipsia, unexplained weight loss, fatigue, visual disturbances, acetone breath, Kussmaul respiration).\n* Any medical or psychological condition judged by the investigator to interfere with study participation or data reliability.\n* Inability or unwillingness to provide informed consent.",{"count":336,"type":21},300,"This project characterizes the longitudinal progression of children and adults who have tested positive for one or more islet cell autoantibodies across the early stages of type 1 diabetes (T1D). Despite advances in screening, limited evidence exists on how clinical, metabolic, and immunological markers evolve over time and predict progression to symptomatic disease. Using a screened cohort, participants are followed for up to 10 years with repeated standardized assessments. The study evaluates whether population-based screening can reduce diabetic ketoacidosis (DKA) at diagnosis and identify early predictors of progression to clinical T1D. Results are expected to improve risk stratification, inform surveillance strategies, and guide the timing of preventive interventions, with implications for clinical practice and health policy.",[339,340,30,341],"Type 1 Diabetes (T1D)","Autoantibodies","Impaired Glucose Tolerance (Prediabetes)",[343,340,344,345,30,346,347,348,315,349,350,351,352,353,354,355],"Diabetes Mellitus, Type 1","Islets of Langerhans","Autoimmune Diseases","Impaired Glucose Tolerance","C-Peptide","Oral Glucose Tolerance Test","Psychological Stress","Early Diagnosis","Disease Progression","Presymptomatic Type 1 Diabetes","Type 1 Diabetes Stage 1","Type 1 Diabetes Stage 2","Type 1 Diabetes Stage 3","2026-04-02",{"date":358,"type":39},"2026-04-08",{"date":360,"type":21},"2026-05",{"date":362,"type":21},"2036-04",{"name":364,"class":46},"Società Italiana di Endocrinologia e Diabetologia Pediatrica",24,{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":22,"phases":376,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":285,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":4},"100632225","cgm-in-acute-ischemic-stroke-100632225","NCT07510919","CGM in Acute Ischemic Stroke","Continuous Glucose Monitoring for Enhanced Management of Hyperglycemia in Persons With Type 2 Diabetes Undergoing Endovascular Therapy for Acute Ischemic Stroke: a Randomized Controlled Trial.","SENSTROKE","Inclusion Criteria:\n\n* Age ≥18 years\n* Acute ischemic stroke treated with endovascular therapy (EVT)\n* Type 2 diabetes mellitus, defined as one of the following:\n* documented diagnosis of type 2 diabetes mellitus\n* use of glucose-lowering medication\n* admission plasma glucose ≥11.1 mmol\u002FL\n* HbA1c ≥48 mmol\u002Fmol (≥6.5%)\n\nExclusion Criteria:\n\n* Current pregnancy\n* Extensive skin infections or dermatological conditions at the intended sensor site\n* Medical situations known to interfere with CGM accuracy, including:\n* Hypotension defined as a systolic blood pressure \\\u003C100 mmHg at 30 and 60 minutes after admission\n* Dialysis treatment\n* Estimated glomerular filtration rate (eGFR) \\\u003C15 mL\u002Fmin\u002F1.73 m²\n* Use of medications known to interfere with CGM accuracy, including:\n* Acetaminophen \\>4 g\u002Fday\n* Dopamine\n* High-dose vitamin C (ascorbic acid)\n* Hydroxyurea \u002F hydroxycarbamide\n* Clinically relevant pancreatic disease\n* Systemic glucocorticoid therapy with a prednisone-equivalent dose \\>5 mg\u002Fday\n* Expected admission to an intensive care unit (ICU)",{"count":375,"type":21},82,[24],"The goal of this randomized clinical trial is to evaluate whether continuous glucose monitoring (CGM) can be used to guide glucose management in patients with type 2 diabetes who are admitted with an acute ischemic stroke and undergo endovascular therapy. Hyperglycemia frequently occurs during hospitalization in stroke and is associated with worse neurological and clinical outcomes. In current clinical practice, glucose levels are monitored using intermittent point-of-care testing (POCT) with finger-prick measurements, which may miss clinically relevant glucose fluctuations. CGM provides continuous glucose measurements and may allow earlier detection of hyperglycemia and more timely glucose management.\n\nThis study is designed as a non-inferiority randomized controlled trial comparing CGM-guided glucose management with standard POCT-guided glucose management. The primary objective is to determine whether CGM-guided glucose management is non-inferior to POCT-guided management in terms of percentage time spent in hyperglycemia (glucose \\>10 mmol\u002FL) during the first 72 hours of hospitalization.\n\nResearchers will compare CGM-guided glucose management to POCT-guided glucose management to evaluate whether CGM can be used as an alternative strategy to guide glucose control in hospitalized stroke patients.\n\nParticipants will:\n\n* Be randomly assigned to either CGM-guided glucose management or standard POCT-guided glucose management\n* Have their glucose levels continuously monitored (blinded in the POCT-guided group) during hospitalization\n* Receive glucose management according to the assigned monitoring strategy, based on the hospital insulin protocol",[379,380,381,30,382],"Acute Ischemic Stroke","Diabetes (DM)","Diabetes Type 2","Stroke","2026-03-31",{"date":385,"type":39},"2026-04-06",{"date":387,"type":21},"2026-04",{"date":389,"type":21},"2028-08",{"name":391,"class":46},"Isala",{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":402,"conditions":403,"keywords":406,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":421},"100553501","shunt-dependency-after-asah---role-of-early-hyperglycaemia-in-csf-and-blood-100553501","NCT06486909","Shunt-dependency After aSAH - Role of Early Hyperglycaemia in CSF and Blood","Shunt-dependency After Aneurysmal Subarachnoid Haemorrhage - the Role of Early Hyperglycaemia in Cerebro-spinal Fluid and Blood","HCP-Glc","Inclusion Criteria:\n\n* 18 years old and older\n* Hospital admission due to an aneurysmal subarachnoid haemorrhage (radiological confirmation needed)\n\nExclusion Criteria:\n\n* Younger than 18 years old\n* Non-aneurysmal subarachnoid haemorrhage (eg. trauma, perimesencephalic subarachnoid haemorrhage, mycotic or flow-associated aneurysms)\n* Previous enrolment into the current study",{"count":401,"type":21},160,"The goal of this study is to confirm the association of early increased glucose levels in cerebro-spinal fluid (CSF) and ventriculo-peritoneal-shunt (VPS)-dependency also evaluating the influence of blood glucose on VPS dependency in patients suffering from an aneurysmal subarachnoid haemorrhage (aSAH). The main questions we aim to answer are:\n\n* Is there an association of glucose levels on VPS dependency in patients requiring extra-ventricular-drain (EVD) placement for aSAH?\n* In addition, if there is, what is the influence the course of glucose levels has on VPS dependency?\n\nGlucose levels in CSF and serum will be measured on admission, or in case of CSF, upon EVD placement. Glucose in CSF will then be measured every day until EVD removal together with serum glucose. Follow-up will be conducted in person after 3 and 6 months.",[404,30,405],"Aneurysm, Ruptured","Hydrocephalus",[407,408,409,410,411],"aneurysmal subarachnoid haemorrhage","hyperglycaemia","hydrocephalus","ventriculo-peritoneal shunt","extra-ventricular drain","2026-03-17",{"date":414,"type":39},"2026-03-18",{"date":416,"type":39},"2024-03-26",{"date":418,"type":21},"2028-09",{"name":420,"class":46},"Isabel Hostettler",3,{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":22,"phases":430,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":47},"100581641","continuous-glucose-monitoring-for-outpatient-diabetes-management-after-hospital-discharge-100581641","NCT06852950","Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge","Inclusion Criteria:\n\n* Non-pregnant adults, ages greater than or equal to 18 years, admitted to VUMC\n* Able to give informed consent\n* Hyperglycemia requiring insulin therapy including subcutaneous insulin injection or continuous subcutaneous insulin infusion (patient's own insulin pump) during hospitalization and at the time of discharge\n* POC glucose or venous glucose levels in the 24 hours prior to participation need to be 70-350 mg\u002FdL\n* Need glucose readings greater than or equal to one time per day\n* Mental status and dexterity adequate to use Libre 3 Plus or Dexcom G7 sensors with Libre 3 or Dexcom G7 application on patient's smartphone\n\nExclusion Criteria:\n\n* Currently using Libre 3 Plus or Dexcom G7 CGMS during hospitalization or have used Libre 3 Plus or Dexcom G7 CGMS in the past 3 months\n* Does not have smartphone compatible with Libre 3 App or Dexcom G7 App\n* Received chemotherapy during current hospitalization\n* Planning on major surgery within 10-15 days\n* Hemodialysis or peritoneal dialysis\n* Requiring vasopressors, intubation, sedation, or admission to an intensive care unit\n* Vitamin C use of more than 500 milligrams per day\n* Hydroxyurea use\n* Acetaminophen use of more than 4 grams per day or 1 gram every 6 hours\n* Significant pitting edema (3+ or greater) i.e. cirrhosis with ascites, congestive heart failure with edema, nephrotic syndrome, or signs of poor perfusion\n* Presentation in diabetic ketoacidosis or hyperosmotic nonketotic state\n* Skin allergy to adhesives",{"count":429,"type":21},60,[24],"This study aims to improve patient awareness of the utility of continuous glucose monitoring systems in blood glucose monitoring and to improve patient satisfaction regarding diabetes care, particularly in the matter of blood glucose monitoring, at the transitions of care from the inpatient setting to the ambulatory setting.",[228,433,30],"Type 1 Diabetes Mellitus (T1DM)","2026-03-02",{"date":436,"type":39},"2026-03-05",{"date":438,"type":39},"2025-03-09",{"date":440,"type":21},"2027-01",{"name":442,"class":46},"Vanderbilt University Medical Center",{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":17,"minAge":276,"maxAge":277,"enrollmentInfo":451,"targetDuration":4,"studyType":22,"phases":452,"briefSummary":453,"conditions":454,"keywords":456,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":47},"100613701","pilot-testing-real-time-engagement-for-learning-to-effectively-control-type-2-diabetes-100613701","NCT07270016","Pilot-Testing Real-Time Engagement for Learning to Effectively Control Type 2 Diabetes","Real-Time Engagement for Learning to Effectively Control Type 2 Diabetes: Pilot Study","REFLECT2DPilot","Inclusion criteria:\n\n* Ages 16-24 years, any sex or gender\n* Diagnosis of type 2 diabetes in childhood (younger than 18 years of age)\n* English-speaking (app in English)\n* Possession of personal smartphone that is compatible with FreeStyle Libre app\n\nExclusion Criteria:\n\n• Cognitive impairment or severe psychiatric conditions that could interfere with participation in behavioral intervention for diabetes self-management",{"count":172,"type":21},[24],"The goal of this study is to pilot test features of a new smartphone app and to gather feedback related to wearing a continuous glucose monitor (CGM) and a Fitbit device, as well as to obtain input on health behavior-focused messages delivered through the app. The study will enroll English-speaking participants aged 16-24 years who were diagnosed with type 2 diabetes before age 18. Participants will be asked to fill out surveys about diabetes, physical activity, and diet before and after wearing a CGM for 30 days. At the end of wearing the CGM, participants will complete an interview about their experience.",[27,30,284,455,315],"Lifestyle (Sedentary Behavior and Physical Activity)",[457,458,459,460],"adolescent","young adult","type 2 diabetes","CGM","2026-02-18",{"date":463,"type":39},"2026-02-20",{"date":465,"type":39},"2026-02-16",{"date":467,"type":21},"2026-12",{"name":294,"class":46},{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":473,"acronym":474,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":22,"phases":478,"briefSummary":479,"conditions":480,"keywords":492,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":506,"locationsCount":47},"100609711","trans-auricular-stimulation-for-postoperative-inflammation-in-spine-surgery-100609711","NCT07218133","Trans-Auricular Stimulation for Postoperative Inflammation in Spine Surgery","TAPIS","Inclusion Criteria:\n\n* Long-segment spinal fusions (defined as constructs spanning at least L2-pelvis for thoracolumbar fusions or C2-T2 for cervical fusions)\n* Ability to undergo a reliable neurologic examination and pain assessments\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years of age\n* Shorter-segment spinal fusions than those described above\n* Undergoing current active cancer therapy\n* Undergoing treatment with immunosuppressive drugs\n* Additional spinal surgery within past 6 months\n* Sustained bradycardia or presence of pacemaker\n* History of substance abuse",{"count":477,"type":21},50,[24],"This study is a randomized controlled trial that will evaluate the effect of non-invasive auricular vagal nerve stimulation on inflammatory markers, glycemic control, postoperative pain, and inflammation-related clinical outcomes after long-segment spinal fusion surgeries when compared to current accepted management.",[481,30,482,483,484,485,486,487,488,489,490,491],"Spinal Fusion","Postoperative Pain Management","Postoperative Care","Spine Disease","Neurologic Deficits","Neurological Disorder","Inflammation","Spine Condition","Spinal (Fusion) Surgery","Cytokine Levels","Spine Fusion",[493,494,495,496,497,498,499,500],"spinal fusion","postoperative pain","glycemic control","inflammation","vagal nerve stimulation","postoperative complications","cytokine","spine surgery","2026-02-17",{"date":463,"type":39},{"date":504,"type":39},"2025-10-08",{"date":467,"type":21},{"name":507,"class":46},"Alexander T. Yahanda",{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":22,"phases":515,"briefSummary":516,"conditions":517,"keywords":520,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":47},"100623739","prospective-exploratory-study-on-the-comprehensive-application-effectiveness-of-exercise-prescription-decision-support-tools-in-the-management-of-patients-with-four-highs-hypertension-hyperglycemia-hyperlipidemia-hyperuricemia-100623739","NCT07400549","Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support Tools in the Management of Patients With \"Four Highs\" (Hypertension, Hyperglycemia, Hyperlipidemia, Hyperuricemia)","Inclusion Criteria:\n\n1. Aged 18 years or older.\n2. Willing to participate in the study and able to provide written informed consent.\n3. Diagnosed with at least one of the following \"Four Highs\" conditions:\n\n   Hypertension: Diagnosed primary hypertension, defined as seated office SBP ≥ 140 mmHg and\u002For DBP ≥ 90 mmHg on at least three non-consecutive days, or currently taking antihypertensive medication. Blood pressure must be controlled while on four or more antihypertensive agents. Diabetes Mellitus: Diagnosed diabetes, defined as having typical symptoms plus random plasma glucose ≥ 11.1 mmol\u002FL, or fasting plasma glucose ≥ 7.0 mmol\u002FL, or 2-hour plasma glucose during OGTT\n\n   ≥ 11.1 mmol\u002FL, or HbA1c ≥ 6.5%, or currently taking glucose-lowering medication. HbA1c level must be between 6.5% and 13.0%. Hyperlipidemia: Diagnosed hyperlipidemia, defined as total cholesterol (TC) ≥ 6.22 mmol\u002FL, or LDL-C ≥ 4.14 mmol\u002FL, or HDL-C \\\u003C 1.04 mmol\u002F L, or triglycerides (TG) \\> 2.26 mmol\u002FL, or currently taking lipid-lowering medication. Hyperuricemia: Diagnosed hyperuricemia, defined as a fasting serum uric acid level \\> 420 μmol\u002FL (7 mg\u002FdL) in men and postmenopausal women, or \\> 360 μmol\u002FL (6 mg\u002FdL) in premenopausal women, on two non-consecutive days under a normal purine diet, or currently taking urate-lowering medication.\n4. Capable of using a smartphone.\n5. A local permanent resident who receives basic public health service management at the designated community health center\u002Fstation or township hospital.\n6. Has not engaged in regular moderate- to vigorous-intensity physical activity (defined as at least 30 minutes per session, on at least 3 days per week) in the past three months.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will be excluded:\n\n1. History or acute episode of cardiovascular or cerebrovascular disease, including: angina pectoris, myocardial infarction, coronary revascularization surgery, stroke (ischemic or hemorrhagic, including transient ischemic attack), symptomatic peripheral arterial disease requiring surgery or diagnosed by vascular imaging, ventricular arrhythmia, uncontrolled atrial fibrillation, congestive heart failure (New York Heart Association Class III or IV), hypertrophic cardiomyopathy, history of aneurysm with diameter ≥ 5.5 cm or prior aneurysm surgery.\n2. Current malignant tumor or history of malignant tumor within the past five years.\n3. Contraindications to exercise, such as bone and joint diseases.\n4. Severe respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), restricted lung volume (due to obesity, pregnancy, or spinal deformity), or cystic fibrosis.\n5. Neuromuscular and degenerative diseases, such as muscular dystrophy, poliomyelitis, and dementia.\n6. Severe mental illness, including schizophrenia, bipolar disorder, eating disorders, or depression (with hospitalization for the condition within the past 6 months).\n7. Movement and other neurological disorders, such as Huntington's disease, torsion dystonia, Parkinson's disease, and certain epileptic disorders.\n8. Severe comorbidities with a life expectancy of less than 24 months.\n9. Plans to relocate from the area within the next three months.\n10. Participation in other physical activity level intervention programs within the six months prior to the screening visit.\n11. Current participation in another randomized clinical trial.\n12. Any other condition that, in the investigator's judgment, may interfere with adherence to the trial protocol.",{"count":279,"type":21},[24],"This study conducted a six-month exploratory clinical trial to evaluate the impact of an exercise prescription mini-program, based on the \"Exercise Guidelines for the 'Four Highs'\", on the physical activity levels and related health indicators of patients with hypertension, hyperglycemia, hyperlipidemia, and hyperuricemia in primary healthcare settings in China.",[91,30,93,518,519],"Hyperuricemia","Digital Intervention",[521,522,523,524],"Digitally-Enabled Health","Chronic Disease Prevention and Control","Sports prescription","Primary health care (PHC)","2026-02-09",{"date":527,"type":39},"2026-02-10",{"date":529,"type":39},"2025-06-01",{"date":531,"type":21},"2026-03-01",{"name":533,"class":246},"China National Center for Cardiovascular Diseases",{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":540,"eligibilityCriteria":541,"healthyVolunteers":56,"sex":542,"minAge":57,"maxAge":221,"enrollmentInfo":543,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":544,"conditions":545,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":47},"100530253","early-investigation-of-glucose-monitoring-after-gestational-diabetes-pilot-100530253","NCT06184373","Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot","Early Investigation of Glucose Monitoring After Gestational Diabetes (ENGAGED): Utility and Acceptability of Continuous Glucose Monitoring in the Early Postpartum Period After Gestational Diabetes Mellitus","ENGAGED","Inclusion Criteria:\n\n* Women with a viable singleton intrauterine pregnancy\n* Able to understand the study, and having understood, provide written informed consent in English\n* Recent pregnancy affected by gestational diabetes\n\nExclusion Criteria:\n\n* Pregestational Diabetes (Type I or Type II)\n* Continued use of diabetes medications (including metformin and insulin) immediately after delivery\n* Preterm delivery (\\\u003C 37 weeks gestation)\n* Twin or higher order gestation\n* No access to a smartphone\n* Unable or unwilling to wear CGM or return for follow up at postpartum mother-infant dyad clinic\n* Participation in this trial in a prior pregnancy\n* History of skin allergy to adhesive products or CGM","FEMALE",{"count":199,"type":21},"One third of women with gestational diabetes (GDM), diabetes diagnosed during pregnancy, have abnormal glucose levels within 3 years after pregnancy, but follow up is low. Continuous glucose monitors (CGM), a small sensor inserted under the skin, may be able to screen women with GDM for diabetes risk. The investigators will ask postpartum women to use CGM at 6-8 weeks postpartum and answer surveys about quality of life after wearing the CGM. The investigators will collect data on blood glucose trends for future studies if participants find CGM use acceptable. The investigators hope to learn if CGM could improve postpartum follow up experiences for people with recent GDM.",[546,30],"Gestational Diabetes","2026-01-20",{"date":549,"type":39},"2026-01-22",{"date":551,"type":39},"2025-06-06",{"date":553,"type":21},"2027-05-30",{"name":555,"class":46},"Ohio State University",{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":563,"enrollmentInfo":564,"targetDuration":4,"studyType":22,"phases":566,"briefSummary":568,"conditions":569,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":573,"completionDateStruct":575,"leadSponsor":576,"locationsCount":47},"100618104","phase-1-a-clinical-trial-evaluating-tqf3250-capsules-in-healthy-adult-subjects-100618104","NCT07327281","A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects","A Phase Ia Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of TQF3250 Capsules in Healthy Adult Subjects After Single Administration and Escalating Doses","Inclusion Criteria:\n\n* Chinese subjects aged above 18 years old (including 18 years old) and below 55 years old (including 55 years old);\n* Those who voluntarily sign a written informed consent form before the trial, have a full understanding of the trial content, process and possible adverse reactions, can communicate well with the researcher, and understand and comply with the requirements of this study;\n* Women of childbearing potential should agree to use effective contraceptive measures during the study and for 6 months after the end of the study;\n* Male weight ≥50 kg, female weight ≥45 kg, body mass index (BMI) between 20-40kg\u002Fm2 (including both ends of the cutoff);\n\nExclusion Criteria:\n\n* Pregnant and lactating women.\n* Those whose vital signs, physical examination, laboratory examination, 12-lead electrocardiogram, anteroposterior chest X-ray, and abdominal ultrasound results during the screening period are abnormal and have clinical significance.\n* Those who have had or currently have diseases\u002Fabnormalities such as heart, endocrine, metabolism, kidney, liver, gastrointestinal tract, skin, infection, blood, nerve or mental illness, or related chronic diseases, or acute diseases, and the researcher assesses that they are not suitable to participate in the trial:\n* Have active tuberculosis during the screening period, or be a close household contact of an untreated active tuberculosis patient.\n* Have a history of severe bacterial, fungal or viral infection within 2 months before randomization, requiring hospitalization with intravenous antibiotics or antiviral drug treatment;\n* Those who have received major surgical treatment, obvious traumatic injury or major surgery during the expected study treatment within 4 weeks before the first medication (except for the surgery stipulated in the program), or have long-term uncured wounds or fractures;\n* Subjects with any bleeding or bleeding events ≥ Common Terminology Criteria (CTC) AE grade 3 within 4 weeks before the first dose;\n* Clinically significant infections occur during the screening period, including but not limited to upper respiratory tract infection, lower respiratory tract infection, herpes simplex, herpes zoster, and require antibiotic or antiviral drug treatment.\n* Have a history of severe herpes zoster or herpes simplex infection, including but not limited to herpetic encephalitis, disseminated herpes simplex, and generalized herpes zoster.\n* Use any systemic cytotoxic or systemic immunosuppressive drugs within 6 months before randomization or within the study period, or use any local cytotoxic or local immunosuppressive drugs within 4 weeks before randomization or within 5 half-lives (whichever is longer) or during the study period.\n* Have received any other biological agents on the market or under investigation within 3 months or 5 half-lives (whichever is longer) before randomization.\n* Have received a live vaccine within 4 weeks before randomization or plan to receive a live vaccine during the study.\n* Those who have undergone surgery within 4 weeks before randomization, or plan to have surgery during the study period.\n* Those who lost blood or donated more than 400 mL of blood within 4 weeks before randomization.\n* Taking any prescription drugs, non-prescription drugs and herbal medicines within 4 weeks before randomization, except vitamin products.\n* Those who have difficulty collecting blood and have a history of fainting from needles or bleeding.\n* Are allergic to any known ingredients of TQF3250 capsules, or have any history of severe drug allergy.\n* Those with a history of drug abuse or positive urine drug screening.\n* Those who smoke more than 5 cigarettes\u002Fday or use a considerable amount of nicotine or nicotine-containing products within 3 months before randomization, or who cannot stop using any tobacco products during the trial.\n* Those who have been alcoholics for a long time or who drank more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of spirits with an alcohol content of 40% or 150 mL of wine) within 3 months before screening, or who cannot abstain from alcohol during the test, or who have a positive alcohol breath test.\n* Those who habitually consume too many caffeinated drinks or foods within 4 weeks before screening. Have consumed grapefruit, bitter orange and the juice of these fruits within 7 days before the first dose, or cannot stop consuming grapefruit, bitter orange and the juice of these fruits during the study;\n* Those who have special dietary requirements and cannot accept standard diet;\n* There are any other reasonable medical, mental or social reasons that the researcher believes to be unable to participate in this study.\n* Those who are unable to comply with the trial plan;\n* Those who participated in and used other clinical trial drugs within three months before the first medication;","55 Years",{"count":565,"type":21},66,[567],"PHASE1","TQF3250 capsule is a biased GLP-1 (glucagon-like peptide-1) receptor agonist developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. By binding to the GLP-1 receptor, it can selectively activate certain signaling pathways of the GLP-1 receptor and reduce activation of other pathways, thereby bringing higher efficacy and lower side effects.",[30],"2025-12-25",{"date":572,"type":39},"2026-01-08",{"date":574,"type":39},"2025-12-18",{"date":467,"type":21},{"name":577,"class":578},"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","INDUSTRY",{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":585,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":254,"enrollmentInfo":587,"targetDuration":4,"studyType":22,"phases":589,"briefSummary":590,"conditions":591,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":47},"100493267","phase-4-semaglutide-treatment-for-hyperglycaemia-after-renal-transplantation-100493267","NCT05702931","Semaglutide Treatment for Hyperglycaemia After Renal Transplantation","Safety and Efficacy of Oral Semaglutide in Hyperglycaemic Patients After Renal Transplantation","Sema-RTx","Inclusion Criteria:\n\n1. Written informed consent obtained before any trial-related procedures are performed\n2. Male or female; age: 18-80 years\n3. Diagnosis of post-transplant hyperglycaemia 10 to 40 days after transplantation: Fasting plasma glucose ≥ 7.0 mmol\u002FL or an oral glucose tolerance test with at plasma glucose ≥ 11.1 mmol\u002FL or Pre-transplant type 2 diabetes: Receiving glucose-lowring treatment prior to kidney transplantation\n4. An eGFR \\> 15 ml\u002Fmin\u002F1.73 m2 10 to 40 days after renal transplantation\n5. Subject must be willing and able to comply with trial protocol\n\nExclusion Criteria:\n\n1. Type 1 diabetes\n2. Dialysis\n3. High risk immunological transplantation (not including ABO-incompatible or re-transplantation)\n4. Early graft rejection (all rejections verified by biopsy, except borderline rejections. Study initiations can begin 5 days after last dose of rejection treatment with methylprednisolone)\n5. Chronic pancreatitis\u002Fprevious acute pancreatitis\n6. Known or suspected hypersensitivity to trial or related products\n7. Use of DPP-4 inhibitors within five days prior to screening\n8. Use of GLP-1RA within 10 days prior to screening\n9. Malignancy (except basal cell carcinoma)\n10. Inflammatory bowel disease\n11. Previous bowel resection\n12. Cardiac disease defined as decompensated heart failure (New York Heart Association class III-IV) and\u002For diagnosis of unstable angina pectoris and\u002For myocardial infarction within the last six months\n13. Any acute condition or exacerbation of chronic condition that would in the investigator's opinion interfere with the initial trial visit schedule and procedures.\n14. Females of childbearing potential who are pregnant, breast-feeding, intend to become pregnant, or are not using adequate contraceptive methods\n15. Impaired liver function (plasma ALAT \\> two times upper reference levels)\n16. Elevated amylase (plasma amylase \\> two times upper reference levels)\n17. Untreated proliferative diabetic retinopathy, untreated diabetic macular edema or active conditions of this type that are not under therapeutic control according\n18. Any condition that clinically significantly impairs the observation of the fundus or anterior chamber",{"count":588,"type":21},104,[258],"Background: Post-transplant hyperglycaemia occurs frequently in renal transplant recipients within the first two weeks after transplantation. Standard-of-care is primarily based on insulin treatment with the adherent risk of hypoglycaemia and weight gain. Semaglutide produces an effective lowering of plasma glucose in diabetes patients with chronic kidney disease (CKD) and leads to a reduction in weight and the incidence of hypoglycaemia. The efficacy of semaglutide is untested in renal transplant recipients, and safety concerns remain, primarily on renal graft function.\n\nObjectives: The primary objective is to establish whether tablet semaglutide (Rybelsus) compared with placebo, both as add-on to standard-of-care, is non-inferior in regulating plasma glucose in patients with hyperglycaemia after renal transplantation. Secondary objectives aim to evaluate the effect of tablet semaglutide on renal graft function, weight, use of insulin, cardiovascular parameters and safety parameters (plasma semaglutide concentration, gastrointestinal side effects, dose of immunosuppressants).\n\nDesign: An investigator-initiated, placebo-controlled, double-blinded, parallel-group, randomised trial.\n\nPopulation: Patients (n = 104) with post-transplant hyperglycaemia or type 2 diabetes and an estimated glomerular filtration rate (eGFR) \\> 15 ml\u002Fmin\u002F1.73 m2.\n\nMethods: Participants diagnosed with post-transplant hyperglycaemia or type 2 diabetes, 10 to 40 days post-transplant, will be randomised 1:1 to either 14 weeks of tablet semaglutide once daily or placebo both as add-on to standard glucose-lowering therapy. Participants will maintain weekly contact with the clinic during the first five weeks and at two to four weeks intervals during the remaining study period. During the trial, each patient will be monitored according to blood laboratory values with safety assessed at every visit by a nephrologist. Pre-prandial plasma glucose will be measured in the morning and evening to adjust glucose-lowering therapy after consultation with an endocrinologist. Double blinded continuous glucose monitoring (CGM) will be performed for 10-14 days from baseline and at weeks 5, 9, and 13.\n\nPrimary endpoint:\n\n\\- Mean sensor glucose (mmol\u002FL) evaluated by CGM\n\nKey secondary endpoints:\n\n* Incidence of hypoglycaemia\n* Body weight (kg)\n* Creatinine (μmol\u002FL)\n* Daily insulin dose (IE per day)\n* Plasma concentration of semaglutide (nmol\u002FL)\n* Blood concentrations of cyclosporine and tacrolimus (μg\u002FL)",[30,592,144],"Renal Transplant Complication Primary Non-Function","2025-12-19",{"date":595,"type":39},"2025-12-29",{"date":597,"type":39},"2024-09-19",{"date":599,"type":21},"2027-12",{"name":601,"class":46},"Rigshospitalet, Denmark",{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":608,"eligibilityCriteria":609,"healthyVolunteers":12,"sex":17,"minAge":303,"maxAge":610,"enrollmentInfo":611,"targetDuration":4,"studyType":22,"phases":613,"briefSummary":614,"conditions":615,"keywords":616,"overallStatus":285,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":4},"100616174","combined-bitter-melon-extract-and-snakehead-fish-powder-supplementation-for-glycemic-control-in-type-2-diabetes-100616174","NCT07302178","Combined Bitter Melon Extract and Snakehead Fish Powder Supplementation for Glycemic Control in Type 2 Diabetes","Effect of Combined Bitter Melon (Momordica Charantia L.) Extract and Snakehead Fish (Channa Striata) Powder Supplementation on Glycemic Status in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial","BM-SF Glycemia","Inclusion Criteria:\n\n* Diagnosed with Type 2 Diabetes Mellitus (DMT2).\n* Fasting plasma glucose ≥ 126 mg\u002FdL and ≤ 200 mg\u002FdL or random blood glucose between 200-300 mg\u002FdL.\n* Age 20-65 years\n* Duration of diabetes 0-15 years.\n* Currently using one class of oral antidiabetic medication (biguanide: metformin).\n* Willing to participate and sign written informed consent.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding; or having impaired kidney or liver function (serum creatinine \\> 1.5 mg\u002FdL; SGOT\u002FSGPT \\> 2× upper limit).\n* Allergy to snakehead fish powder (Channa striata) or bitter melon extract (Momordica charantia).\n* Using antidiabetic medications other than metformin, or unable\u002Funwilling to comply with study procedures.","65 Years",{"count":612,"type":21},80,[24],"Type 2 diabetes mellitus (T2DM) remains a major global health problem due to its high prevalence, long-term complications, and substantial economic burden. Conventional antidiabetic therapies, including insulin and oral hypoglycemic agents, may cause significant side effects during long-term use and are contraindicated in certain clinical conditions. Therefore, safe and effective herbal-based alternatives are needed.\n\nPrevious preclinical and early clinical studies have shown that bitter melon (Momordica charantia L.) and snakehead fish (Channa striata) possess antidiabetic and anti-inflammatory properties, including improvement in glucose regulation, stimulation of insulin secretion, and regeneration of pancreatic cells. However, clinical evidence on their combined use remains limited.\n\nThis randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effect of daily supplementation with a combination of bitter melon extract and snakehead fish powder on glycemic status in adults with Type 2 diabetes mellitus. Ninety eligible participants will be randomly assigned to a treatment group receiving 500 mg\u002Fday of the herbal combination or a placebo for 4 weeks. Glycemic status will be assessed primarily through glycated albumin (GA) levels.\n\nThe findings of this study are expected to provide scientific evidence regarding the safety and efficacy of this herbal combination as a complementary antidiabetic therapy.",[228,30],[617,618,619,620],"Bitter melon extract","Momordica charantia","Channa striata","Glycemic status","2025-12-11",{"date":623,"type":39},"2025-12-24",{"date":625,"type":21},"2026-01-01",{"date":627,"type":21},"2026-06-01",{"name":629,"class":46},"Universitas Muhammadiyah Surakarta",{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":4,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":637,"targetDuration":4,"studyType":22,"phases":639,"briefSummary":640,"conditions":641,"keywords":646,"overallStatus":285,"whyStopped":4,"lastUpdateSubmitDate":652,"lastUpdatePostDateStruct":653,"startDateStruct":655,"completionDateStruct":657,"leadSponsor":659,"locationsCount":4},"100613772","optimizing-enteral-nutrition-regimen-for-critically-ill-patients-100613772","NCT07270939","Optimizing Enteral Nutrition Regimen for Critically Ill Patients","Optimizing Enteral Nutrition: A Comparative Study of 18-Hour, 20-Hour, and 24-Hour","Inclusion Criteria\n\nParticipants must meet ALL of the following criteria to be eligible for the study:\n\n1. Patients aged ≥ 18 years.\n2. Patients expected to require enteral nutrition (EN) for ≥ 7 days.\n3. Critically ill, mechanically ventilated patients in the ICU.\n4. New patients initiating EN in the critical care unit.\n5. Patients receiving EN via:\n\n   * a nasogastric (NG) tube.\n   * orogastric (OG) feeding tube.\n\nExclusion Criteria:\n\n1. Patients with contraindications to enteral feeding or pre-existing gastrointestinal disorders, including:\n\n   * Active GI bleeding.\n   * Progressive GI disease.\n   * Recent GI tract resection.\n2. Indication for a special diet formula.\n3. Need for a large volume of feeding (as determined by the clinical team).\n4. Pre-existing hepatic failure.\n5. Use of a nasojejunal tube, gastrostomy, or jejunostomy.\n6. Pregnancy confirmed via β-hCG testing for women of childbearing potential.\n7. Insulin-dependent diabetes mellitus.",{"count":638,"type":21},150,[24],"Clinical Trial The goal of this clinical trial is to learn whether different enteral feeding cycles (18-hour, 20-hour, or standard 24-hour continuous feeding) improve outcomes for critically ill ICU patients who need tube feeding. It will also look at tolerance, nutrition delivery, and safety.\n\nThe main questions it aims to answer are:\n\nDo shorter feeding cycles (with fasting windows) reduce ICU length of stay?\n\nDo they lower the risk of infections like ventilator-associated pneumonia?\n\nHow do they affect calorie delivery, blood sugar control, and gastrointestinal tolerance?\n\nResearchers will compare:\n\nContinuous 24-hour feeding (standard care)\n\n20-hour feeding with a 4-hour fasting window\n\n18-hour feeding with a 6-hour fasting window\n\nParticipants will:\n\nBe critically ill adults in the ICU who require at least 7 days of enteral feeding\n\nBe randomized to one of the three feeding schedules\n\nReceive daily monitoring of calories, protein, blood sugar, and GI tolerance\n\nHave outcomes measured, including ICU length of stay, infections, metabolic control, and feeding tolerance",[642,643,644,30,645],"Critical Illness","Enteral Nutrition","Ventilator Associated Pneumonia","Feeding Intolerance",[647,648,649,650,651],"Cyclic feeding","Feeding window","Critical care nutrition","Gastrointestinal tolerance","Nutritional adequacy","2025-11-26",{"date":654,"type":39},"2025-12-08",{"date":656,"type":21},"2025-12-30",{"date":658,"type":21},"2026-11-30",{"name":660,"class":578},"Hamad Medical Corporation",{"id":662,"slug":663,"hasResults":12,"nctId":664,"briefTitle":665,"officialTitle":666,"acronym":667,"eligibilityCriteria":668,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":669,"targetDuration":4,"studyType":22,"phases":670,"briefSummary":671,"conditions":672,"keywords":675,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":684,"lastUpdatePostDateStruct":685,"startDateStruct":687,"completionDateStruct":689,"leadSponsor":691,"locationsCount":161},"100449420","monitoring-and-managing-glucose-levels-in-people-with-pancreatic-cancer-100449420","NCT05132244","Monitoring and Managing Glucose Levels in People With Pancreatic Cancer","Pancreatic Cancer Glucose Assessment and Regulation Study","PEGASUS","Inclusion Criteria:\n\n* Histological\u002Fcytological diagnosis of pancreatic ductal adenocarcinoma (PDAC).\n* Planned to undergo first-line systemic therapy with FOLFIRINOX.\n* Age greater than or equal to 18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n* Adequate bone marrow and organ function as defined by the following laboratory values:\n\n  1. Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10\\^9\u002FL.\n  2. Platelet count greater than or equal to 75 x 10\\^9\u002FL.\n  3. Hemoglobin greater than or equal to 9.0 g\u002FdL.\n  4. Estimated glomerular filtration rate (GFR) by Cockroft-Gault equation OR 24 hour urine collection greater than or equal to 40 ml\u002Fmin.\n  5. Creatinine clearance greater than or equal to 40 mL\u002Fmin using Cockcroft-Gault formula.\n  6. Potassium within normal limits, or corrected with supplements.\n  7. International normalized ratio (INR) less than or equal to 1.5.\n  8. Total serum bilirubin less than or equal to 2 x upper limit of normal (ULN) (any elevated bilirubin should be asymptomatic at enrollment) except for participants with documented Gilbert's syndrome who may only be included if the total bilirubin less than or equal to 3 x ULN or direct bilirubin less than or equal to 1.5 x ULN).\n  9. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 2.5 x ULN (or less than or equal to 5 x ULN if liver metastases are present).\n* Able to understand and voluntarily sign the informed consent form.\n* Able to comply with the study visit schedule and other protocol requirements.\n* Able to swallow oral medications and has no contraindications to subcutaneous insulin injections.\n* Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 at baseline.\n* Life expectancy of more than 90 days as judged by the study doctor.\n\nExclusion Criteria:\n\n* Absence of distant or lymph node metastases. Participants with borderline resectable or locally advanced PDAC are not eligible.\n* Received prior systemic therapy (chemotherapy or any other anti-cancer agent) for treatment of metastatic PDAC. Participants who received adjuvant chemotherapy after surgical resection of early stage disease are eligible.\n* Currently receiving anti-cancer therapy (chemotherapy or any other anti-cancer agent).\n* Not fit for combination chemotherapy as judged by the study doctor.\n* Presence of brain metastases.\n* Known diagnosis of type I diabetes where strict glucose control and close Endocrinology follow-up is already indicated.\n* Known diagnosis of type II diabetes and already followed by Endocrinologist.\n* Female participants with a positive pregnancy test.\n* Participants who are not safe to include in the study as judged by the study doctor for any medical or non-medical reason.\n* Unable to comply with study assessments and follow-up.",{"count":477,"type":21},[24],"This study will investigate whether or not it is feasible to closely monitor and manage glucose levels in people with pancreatic cancer. It will also investigate what impact glucose management may have on pancreatic cancer.\n\nThis is a pilot study that will use continuous glucose monitors (CGM) to monitor glucose levels in approximately 50 participants with pancreatic cancer. Participants will receive standard chemotherapy with a combination of up to four drugs to treat their pancreatic cancer: oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin (FOLFIRINOX). To treat high glucose levels, participants will be randomly assigned to one of two groups: Group 1 will receive anti-hyperglycemic treatment as guided by an endocrinologist with the aim of maintaining glucose levels between 4 and 10 mmol\u002FL; Group 2 will receive anti-hyperglycemic treatment if their glucose levels are above 15 mmol\u002FL, which is standard care. Participants in both Groups 1 and 2 will receive standard anti-hyperglycemic treatments: metformin, insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, sodium glucose co-transporter (SGLT2) inhibitors, and dipeptidyl peptidase 4 (DPP-4) inhibitors.\n\nAfter 4 cycles of FOLFIRINOX, the CGM will be removed but any anti-hyperglycemic treatments will continue as needed. If participants discontinue treatment with FOLFIRINOX, they will continue to be followed for survival and subsequent anti-cancer therapy and will continue follow-up for glucose-related concerns at the discretion of their endocrinologist and\u002For medical oncologist.",[673,674,30],"Pancreatic Cancer","PDAC - Pancreatic Ductal Adenocarcinoma",[676,677,678,679,680,681,682,683],"FOLFIRINOX","Continuous Glucose Monitor","Feasibility","Glycemic management","Endocrinologist","Intensive glucose intervention","Pilot","Glucose control","2025-09-17",{"date":686,"type":39},"2025-09-22",{"date":688,"type":39},"2024-04-16",{"date":690,"type":21},"2027-04",{"name":692,"class":46},"British Columbia Cancer Agency",{"id":694,"slug":695,"hasResults":12,"nctId":696,"briefTitle":697,"officialTitle":697,"acronym":698,"eligibilityCriteria":699,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":700,"targetDuration":4,"studyType":22,"phases":701,"briefSummary":702,"conditions":703,"keywords":707,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":709,"lastUpdatePostDateStruct":710,"startDateStruct":712,"completionDateStruct":714,"leadSponsor":715,"locationsCount":47},"100602142","targeting-metabolic-syndrome-from-the-emergency-department-through-mixed-methods-pilot-trial-100602142","NCT07119658","Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial","METS","Inclusion Criteria:\n\n* Ambulatory adults (18 years of age) presenting to the emergency department setting\n* BMI 30 kg\u002Fm2\n* Prior diagnosis of at least one additional comorbid component of metabolic syndrome: hypertension, hyperglycemia, dyslipidemia\n* Clinical plan for discharge\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Pregnant patients\n* Unable to safely ambulate (including patient or family perception of inability to safely ambulate)\n* Lack of access to smart phone\n* Unable or unwilling to wear Fitbit accelerometer device\n* Unable to obtain informed consent",{"count":199,"type":21},[24],"The objective of this study is to pilot a multifaceted, optimized intervention for metabolic syndrome (MetS) in emergency department patients to establish feasibility. Participants (n=20) will be randomized to intervention or control (usual care). The composite intervention will include an educational video outlining the adverse effects of MetS and the benefit of walking, a written exercise prescription with a defined goal of walking 150 minutes per week, a Fitbit accelerometer device, resources for healthy eating practices, periodic text message reminders, and an urgent referral to primary care and our health system's Healthy Me clinic for follow-up visit. Investigators hypothesize that this approach will change patient understanding and motivation to increase physical activity and healthy eating habits.",[91,30,704,64,705,144,93,706],"Dyslipidemia","Obesity &Amp; Overweight","Emergency Medicine",[64,708],"Emergency Department","2025-08-05",{"date":711,"type":39},"2025-08-13",{"date":713,"type":39},"2025-07-08",{"date":290,"type":21},{"name":189,"class":46}]